

New medications added to Security Health Plan’s Medicare Part B step therapy program

The Centers for Medicare and Medicaid Services (CMS) previously issued guidance that provides Medicare Advantage plans the option of applying step therapy for physician-administered Part B drugs in a way that lowers costs and improves the quality of care for Medicare beneficiaries.

Security Health Plan first implemented step therapy requirements on May 1, 2019, and has added to the program periodically for NEW starts of certain targeted drugs.

For dates of service on or after Apr. 1, 2023, the following drugs will be added to the program. In-scope indications include all medically accepted indications unless otherwise noted in the table below. These step therapy requirements apply to commercial lines of business as well as Medicare.

Requested Product	Preferred Alternative Agent(s)	Special Comments
Rolvedon (J3590)	Neulasta (J2505), Udenyca (Q5111), Fulphila (Q5108)	N/A

In addition, Alymsys (J9999) was previously preferred but will be moved to non-preferred.

Requested Product	Preferred Alternative Agent(s)	Special Comments
Alymsys (J9999)	Mvasi (Q5107), Zirabev (Q5118)	N/A

Implementation will continue to be for new starts only (no use in the previous 365 days), meaning no beneficiaries currently receiving eligible step therapy drugs under Part B will have to change their drug. Step therapy prior authorization will be managed through Security Health Plan’s specialty pharmacy medication partner, Magellan.

Please call 1-800-424-8243 or visit www.mrxgateway.com.